Literature DB >> 17029259

Longitudinal study of the motor response to levodopa in Parkinson's disease.

Benjamin G Clissold1, Craig D McColl, Katrina R Reardon, Mark Shiff, Peter A Kempster.   

Abstract

In this prospective study of 34 patients with Parkinson's disease, measurements of the short duration levodopa motor response have been performed in defined off states at 3 yearly intervals over a mean period of 11.4 years from the point of commencement of levodopa treatment. Twenty-two patients were still available for study; 10 had died and 2 were lost to follow-up. The levodopa motor response amplitude increases over the first 5 years of treatment, and thereafter, on and off scores worsen in parallel with conservation of the response. Patients who developed motor fluctuations within the first 5 years of treatment had, on average, a stronger response to levodopa with significantly better on phase motor function (P = 0.003). Although the proportion of "midline" motor disability (affecting gait, balance, and cranial motor function) increases with time, these deficits do not actually become unresponsive to levodopa. Patients who developed dementia had a significantly more rapid decline in motor function. The latest graph of serial scores for the whole cohort shows an upward curving or exponential increase in motor disability after the first decade of treatment. Applying a notional untreated disability line to this graph--an estimate of the disability that would have accrued if drugs had never been given--we suggest that the long-duration response to levodopa eventually runs down with disease progression. Copyright 2006 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17029259     DOI: 10.1002/mds.21126

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  12 in total

1.  Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.

Authors:  Bonnie G Garcia; M Diana Neely; Ariel Y Deutch
Journal:  Cereb Cortex       Date:  2010-01-29       Impact factor: 5.357

Review 2.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

3.  Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons.

Authors:  M D Neely; D E Schmidt; A Y Deutch
Journal:  Neuroscience       Date:  2007-07-17       Impact factor: 3.590

4.  The effect of dopamine replacement therapy on haptic sensitivity in Parkinson's disease.

Authors:  Kuan-yi Li; Kristen Pickett; Igor Nestrasil; Paul Tuite; Jürgen Konczak
Journal:  J Neurol       Date:  2010-07-14       Impact factor: 4.849

Review 5.  Axial disability and deep brain stimulation in patients with Parkinson disease.

Authors:  Alfonso Fasano; Camila C Aquino; Joachim K Krauss; Christopher R Honey; Bastiaan R Bloem
Journal:  Nat Rev Neurol       Date:  2015-01-13       Impact factor: 42.937

Review 6.  The missing, the short, and the long: Levodopa responses and dopamine actions.

Authors:  Roger L Albin; Daniel K Leventhal
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

Review 7.  The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

Authors:  Xiaoxi Zhuang; Pietro Mazzoni; Un Jung Kang
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

8.  The Effect of Dopaminergic Medication on Joint Kinematics during Haptic Movements in Individuals with Parkinson's Disease.

Authors:  Kuan-Yi Li; Pei-Yi Chu; Kristen A Pickett
Journal:  Behav Neurol       Date:  2017-04-17       Impact factor: 3.342

9.  Treatment Responsiveness of Motor Features in Parkinson's Disease: A Matched Case-Control Analysis.

Authors:  Angus D Macleod; Carl E Counsell
Journal:  Mov Disord Clin Pract       Date:  2019-11-21

10.  Effect of Age and Disease Duration on the Levodopa Response in Patients with Advanced Parkinson's Disease for Deep Brain Stimulation of the Subthalamic Nucleus.

Authors:  Dursun Aygun; Ersoy Kocabicak; Mustafa Onur Yildiz; Yasin Temel
Journal:  Front Neurol       Date:  2016-06-27       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.